Loading...
Although population-wide screening for pancreatic cancer is not recommended, data are emerging to support surveillance of high-risk individuals to identify disease at an early stage (NEJM JW Oncol Hematol Dec 2022 and J Clin Oncol 2022; 40:3257). Among individuals with significantly increased risk for pancreatic cancer, those who may be candidates for screening include patients with a germline pathogenic variant in CDKN2A.
To address the potential benefit of screening in this population, investigators in the Netherlands now report results of a prospective, 20-year, pancreatic cancer surveillance program (initiated in 2000) involving 347 germline CDKN2A pathogenic variant carriers. Of this cohort, the median age was 49, 58% were female, 38% h…